Status:
COMPLETED
Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity
Lead Sponsor:
Allergan
Conditions:
Stroke
Muscle Spasticity
Eligibility:
All Genders
21+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety of repeated doses of Botulinum Toxin Type A for the treatment of focal upper limb poststroke spasticity
Eligibility Criteria
Inclusion
- Medically stable poststroke patients with spastic muscles in the upper limb
Exclusion
- Stroke within 6 months of study enrollment
- Previous therapy with Botulinum Toxin Type A for treatment of any condition prior to 4 months of enrollment, for treatment of any condition prior to 01 January 1998
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2004
Estimated Enrollment :
279 Patients enrolled
Trial Details
Trial ID
NCT00651729
Start Date
April 1 2003
End Date
December 1 2004
Last Update
May 28 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Indianapolis, Indiana, United States
2
Vancouver, British Columbia, Canada